Advancements in Oncology
Advertisement
Dr. Eng opines on how the ESOPEC study will alter the treatment paradigm for patients with esophageal/GEJ adenocarcinoma.
Dr. Eng comments on how she approaches treatment considerations and management for her younger patients with colon cancer.
Dr. Eng explains how she makes sense of the stage 4 third-line therapy options to administer to her colon cancer patients.
Dr. Eng shares what the COMMIT study suggest about colon cancer and this study's applicability outside of liver metastasis.
Dr. Eng provides her thoughts on ctDNA upfront, sequential, and combined with NGS testing for patients with colon cancer.
The trio pondered the evolving landscape of upper GI cancer treatments, particularly in localized and advanced stages.
The trio delved into the nuances of dosing strategies for TAS-102 and fruquintinib for colorectal cancer, offering insights.
The trio highlighted the evolution of genetic mutations in colon cancer, pointing to recent studies on NGS.
Dr. Eng first shared her expertise on the current approaches to treating colon cancer, focusing on the use of ctDNA.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.